trending Market Intelligence /marketintelligence/en/news-insights/trending/pkxvtjfj56n5fnoli_upfa2 content esgSubNav
In This List

Pieris Pharmaceuticals adds board member

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Pieris Pharmaceuticals adds board member

Boston-based Pieris Pharmaceuticals Inc. added Peter Kiener as a member of its board.

Kiener served as chief scientific officer at Sucampo AG until its acquisition by Mallinckrodt earlier this year. He has also served as the chief scientific officer at Ambrx Inc. and as the president and co-founder of Zyngenia Inc., which develops monoclonal antibodies to treat oncology and inflammatory diseases.

He has also held research and development positions at MedImmune LLC and Bristol-Myers Squibb Co.

Pieris has several preclinical and clinical-stage drugs in the pipeline based on its Anticalin protein technology. The company's focus is on immuno-oncology and respiratory diseases, for which it has partnered with Servier International and AstraZeneca PLC respectively.